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Abstract 19 
 20 
Aluminium salts are the most widely used vaccine adjuvants and phosphate is known to modulate the 21 
antigen-adjuvant interaction. Here we report an unexpected role of phosphate buffer in an anthrax 22 
vaccine (SparVax™) comprising recombinant Protective Antigen (rPA) and aluminium oxyhydroxide 23 
(AlOH) adjuvant (Alhydrogel™). Phosphate ions bind to AlOH to produce an aluminium phosphate 24 
surface with a reduced rPA adsorption coefficient and binding capacity. However, these effects 25 
continued to increase as free [phosphate] increased and the binding of rPA changed from endothermic 26 
to exothermic. Crucially, phosphate restored the thermostability of bound rPA so that it resembled the 27 
soluble form, even though it remained tightly bound to the surface. Batches of vaccine with either 28 
0.25 mM (sub-saturated) and 4 mM (saturated) phosphate, tested in a disease model at batch release, 29 
showed that the latter was significantly more potent. Both formulations retained their potency for 30 
three years. The strongest aluminium adjuvant effects are thus likely to be via weakly attached or 31 
easily released, native state antigen proteins. 32 
Abbreviations 33 
rPA; recombinant protective antigen  from Bacillus anthracis expressed in and purified from 34 
Escherichia coli.  35 
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Introduction 36 
To combat infectious diseases subunit vaccines, comprising a recombinant antigen and an immune 37 
stimulating adjuvant, are increasingly important. These vaccines provide a safer alternative to using 38 
live attenuated/inactivated micro-organisms or partially purified microbial extracts, while still 39 
promoting protective immunity in an individual (1). Currently under development is an anthrax 40 
subunit vaccine (SparVax™) for anthrax pre- and post-exposure prophylaxis treatment. It uses a 41 
recombinant protein component, Protective Antigen (rPA), of the anthrax tripartite toxin, (2) as the 42 
target antigen for toxin neutralizing antibody production. By itself, rPA is a relatively poor 43 
immunogen and, to provide protection against anthrax infection, needs to be formulated with an 44 
adjuvant. In line with several recombinant protein sub-unit vaccines (3), an aluminium-based adjuvant 45 
was chosen since these mineral adjuvants have been shown to be highly effective and, having been 46 
administered to millions of people, have an extensive safety record. More specifically the selected 47 
adjuvant was Alhydrogel®, which is essentially aluminium oxyhydroxide and, with a net positive 48 
surface charge, is known to bind to acidic proteins like rPA (pI= 5.6) (4). 49 
The mechanism by which aluminium salts act as adjuvants for vaccine antigens has recently been 50 
intensively investigated at the cellular level. Originally they were considered to simply act as a depot 51 
maintaining local antigen concentration (5) but there are now many observations which suggest that 52 
more subtle effects lead to increased protection(6). These include NLRP3 inflammasome activation, 53 
prostaglandin production, release of endogenous danger signals such as uric acid or DNA following 54 
cell death, binding to membrane lipids and B cell priming (6, 7). In a series of papers, Hem and 55 
colleagues showed that the strength of antigen adsorption to an aluminium-containing adjuvant is 56 
inversely related to the immune response(8-10). They also showed that antigens do not need to be 57 
bound to the aluminium salt in order to benefit from the adjuvant effect (11) and furthermore that 58 
interstitial fluid can contribute to dissociation of the antigen-adjuvant complex in newly formulated 59 
vaccines but less so in older samples(12). Recently it was demonstrated that aluminium adjuvanted 60 
antigen dissociates readily from the adjuvant and the removal of the injection site and associated alum 61 
depot 2 h after injection does not impair the immune response, thus questioning the role of Alhydrogel 62 
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in forming a stable depot of antigen(13). These results fundamentally question the role of the physical 63 
interaction between antigen and adjuvant. We therefore wished to determine if the physical behaviour 64 
of different formulations of a clinically relevant antigen-Alhydrogel complex has any correlation with 65 
its short or long term potency. 66 
Structurally, Alhydrogel® comprises fine crystalline particles made of corrugated layers of aluminium 67 
oxyhydroxide (14). Each aluminium atom is coordinated by four oxygen atoms and two hydroxyl 68 
groups (15), the layers are held together by hydrogen bonding and, in aqueous solutions, the particles 69 
form aggregates ranging from 1 to 10 µm in diameter (16). Unmodified Alhydrogel particles have a 70 
point of zero charge of approximately 11, i.e., the pH at which the charge on the colloidal particle is 71 
zero. Therefore, Alhydrogel is positively charged at physiological pH and spontaneously adsorbs 72 
acidic proteins by an electrostatic attraction mechanism (17). Mixing the rPA protein with the 73 
Alhydrogel adjuvant, at the appropriate concentrations readily, and very rapidly, forms the rPA-74 
Alhydrogel (rPA-AlOH) complex (18).  75 
Structural studies have shown that Alhydrogel-bound proteins, including rPA, preserve their 76 
secondary (19, 20), tertiary (18), and quaternary structure (21, 22) but exhibit a decreased thermal 77 
stability compared to their free counterparts in solution (23, 24). At the surface of adjuvant particles, 78 
bound proteins form a monolayer in which individual biomolecules are closely packed together with 79 
no apparent preference for any particular surface orientation. Moreover, the size of protein-adjuvant 80 
particles appears to be similar to that of adjuvant particles alone (22, 25) so particle aggregation is not 81 
a feature of the process. 82 
In addition to the rPA-AlOH complex, the formulation comprised two excipients: (1) saline at 83 
physiological levels was included in the formulation to ensure that the anthrax vaccine was isotonic 84 
for recipient comfort upon injection and (2) phosphate ions were included with the initial intention of 85 
providing buffering capacity. However, it is well established that phosphate groups will ligand 86 
exchange with aluminium oxyhydroxide resulting in a modification of the surface properties of the 87 
colloidal particles (26). For this sub-unit vaccine formulation, the immediate concern is that the ligand 88 
exchange reaction modifies the point of zero charge to such an extent that the acidic recombinant 89 
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protein becomes desorbed from the aluminium oxyhydroxide surface, resulting in high levels of 90 
unbound antigen with potential effects on the subsequent immune response. Furthermore, removing a 91 
phosphate ion from solution and replacing it with a hydroxyl group has the potential to modify the pH 92 
of the formulation. Indeed, it has also been shown that the pH microenvironment adjacent to the 93 
aluminium oxyhydroxide particle surface is approximately two pH units higher than that of the 94 
surrounding solution (27). Since antigen binding occurs as a monolayer at the surface of the 95 
aluminium oxyhydroxide particle (22), it will reside in this microenvironment and be subject to 96 
conditions different from those of the bulk solution.  97 
As discussed above, Hem and co-workers (27) have shown phosphate to be a modifying agent for 98 
aluminium oxyhydroxide, due to the effects of the ligand exchange reaction and in addition to its role 99 
as a buffer. Furthermore, by modifying the physical nature of the aluminium oxyhydroxide, phosphate 100 
may also affect the potency of any vaccine where it is used as an adjuvant.  101 
Since phosphate comprises the physiological buffering agent of the anthrax vaccine, we have studied 102 
the effect of phosphate ions on the rPA-AlOH formulation. The aim of these studies was to 103 
understand the effect of phosphate on the rPA-AlOH colloidal particles, the structure of the protein 104 
antigen, the stability of the formulation, and most importantly the potency of the rPA-AlOH vaccine. 105 
The data demonstrate that both surface bound and free phosphate ions have subtle effects on the 106 
firmly bound rPA causing it to behave like a soluble protein. This in turn resulted in an enhanced 107 
immune response and helped to explain why the adsorption coefficient of rPA-AlOH binding is 108 
inversely related to potency (10). 109 
 110 
Materials and Methods 111 
rPA-Alhydrogel formulation 112 
All chemicals and reagents were purchased from either Sigma-Aldrich Company Ltd (UK) or Melford 113 
Laboratories (UK), unless otherwise stated.  114 
Recombinant protective antigen (rPA) was manufactured to cGMP by Avecia Biologics, Billingham, 115 
U.K. rPA was expressed as inclusion bodies using Escherichia coli strain UT5600 (DE3)/pET29a. 116 
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After solubilisation with urea the protein was refolded by dilution and then purified using anion-117 
exchange and hydrophobic interaction chromatography. The highly purified rPA was then buffer 118 
exchanged into phosphate buffered saline by diafiltration (28) and the concentration adjusted to give ~ 119 
1.5 mg/ml. Aliquots of protein were stored at -80 0C until required. Aluminium hydroxide gel 120 
adjuvant (AlhydrogelTM) was purchased from either Brenntag Biosector (Denmark) or Sigma-Aldrich 121 
Company Ltd (UK).  122 
rPA was adsorbed to Alhydrogel adjuvant by adding the protein solution to the adjuvant suspension at 123 
ambient temperature. Unless otherwise stated, the rPA-AlOH formulations comprised 200 µg/ml rPA, 124 
2.6 mg/ml Alhydrogel, 0.9% NaCl, 0.04% Tween 20, pH 7.0 with differing concentrations of 125 
phosphate. rPA concentrations were measured at 280 nm (A280), using an extinction coefficient of 126 
1.176 AU/mg/ml to give the concentration of rPA in solution in mg/ml, using 1 cm path length quartz 127 
cuvettes (Hellma, GmbH & Co., Germany) in a UV-1800 UV-visible spectrophotometer (Shimadzu, 128 
Japan).  129 
 130 
Alhydrogel Phosphate Titration  131 
Phosphate buffer (0 - 5 μmol) was added to 3 mg of Alhydrogel in 1 ml water and vortexed. The 132 
samples were incubated for 1 hour with agitation at ambient temperature and then centrifuged at 133 
20000 x g for 1 minute. The supernatant was then analysed for phosphate using a colorimetric assay 134 
(Bencini et al., 1983). 400 μl of sample was added to 1200 μl of reagent mixture (100 mM zinc 135 
acetate, 15 mM ammonium molybdate, pH 5.0), vortexed and allowed to react for 1 minute before 136 
measuring absorbance at 350 nm in a UV-1800 UV-visible spectrophotometer (Shimadzu, Japan) 137 
using 1 cm path length quartz cuvette (Hellma, GmbH & Co., Germany). Values were calibrated 138 
against a phosphate standard curve of NaH2PO4/Na2HPO4, pH 7.0 containing 0 - 700 μM phosphate.  139 
 140 
rPA Langmuir adsorption isotherms 141 
rPA was combined with Alhydrogel in phosphate buffer (0 – 50 mM) and the samples were incubated 142 
for 1 hour with gentle agitation at an ambient temperature. Subsequently, all samples were centrifuged 143 
for 5 min at 14600 x g using a bench top centrifuge and supernatant [rPA] was assessed by A280. The 144 
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amount of rPA adsorbed to Alhydrogel was calculated by subtracting the rPA remaining in solution 145 
from the total added. Adsorption coefficient (K) and binding capacity (Γmax) were obtained by 146 
linearizing the Langmuir equation (10, 29)and determined using 1/y intercept and 1/slope, 147 
respectively.  148 
 149 
Zeta Potential Measurements 150 
Zeta potential was determined using a Zetasizer (Malvern, U.K.). 1 ml samples of rPA-AlOH were 151 
introduced into the DTS1060 capillary cells and pre-equilibrated at 20oC for 2 min prior to 152 
electrokinetic analysis, as per manufacturer’s instructions. The zeta potential was automatically 153 
determined by the Zetasizer software using the Smoluchowski equation. Samples were tested in 154 
triplicate with an average of 6 readings per sample.  155 
 156 
Circular dichroism 157 
Conventional circular dichroism becomes inaccurate when using particulates that settle and in highly 158 
scattering solutions (30). To avoid these problems we used a solid-state CD technique reported 159 
previously which reduces the effects of light scattering and protein aggregation by the use of a 160 
specialised rotating sample cell holder(31). The raw data was corrected for protein concentration and 161 
converted into differential extinction coefficient (Δε) units (M-1 cm-1). using the molar concentration 162 
of amino acid residues for far UV CD and for near-UV the molar concentration of rPA. The spectra 163 
were measured in triplicate from freshly prepared independent samples.  164 
 165 
Intrinsic tryptophan fluorescence 166 
Tryptophan fluorescence was measured at ambient temperature using a Cary Eclipse 167 
spectrofluorometer (Agilent, UK) with an excitation wavelength of 280 nm and the emission spectra 168 
were measured between 300 and 400 nm. rPA-Alhydrogel® samples were directly measured in a 1 169 
cm path length quartz cuvette (Hellma, UK). To prevent sedimentation and to maintain the 170 
homogeneity of the suspended rPA-Alhydrogel particles, samples were stirred using a small magnetic 171 
stirring bar placed inside the cuvette. Data were comparable with that obtained from front face 172 
 8
illumination of a triangular cuvette but stirring was more reliable in the standard square footprint 173 
design. 174 
In order to provide a more accurate evaluation of the emission spectra, the barycentric mean (the 175 
centre of an integrated emission curve) was determined using the equation:  176 
 177 
where, λm is the barycentric mean, λ is the wavelength, Fλ is the point fluorescence at wavelength λ 178 
(32). Thermal denaturation was monitored via tryptophan fluorescence using a Cary Eclipse equipped 179 
with a temperature controller and a 1 cm path length quartz cuvette (Hellma, UK) with a plastic lid. A 180 
small magnetic stirring bar inside the cuvette stirred the samples while the temperature was raised 181 
from 25oC to 65oC at a rate of 1oC min-1. The variation of fluorescence (F) with increasing 182 
temperature (T) was measured using wavelengths of 280 nm for excitation and 340 nm for emission. 183 
The transition temperature was determined as the peak value of the first order derivative dF /dT.  184 
 185 
Calorimetry  186 
Differential scanning calorimetry measurements were made using VP-DSC micro-calorimeter 187 
(MicroCal, UK). Prior to analysis, all samples were de-gassed in a ThermoVac unit (MicroCal, UK). 188 
Samples of rPA-Alhydrogel 0.3 mg/ml PA; 3 mg/ml phosphate saturated Alhydrogel; 0, 1, 5, 10, 20, 189 
and 50 mM free phosphate were analysed. Samples were scanned between 25oC and 60oC at the rate 190 
of 10C min-1 and Alhydrogel diluted in the formulation buffer was used as a reference. Scans were not 191 
completely reversible and thus the quantitative thermodynamic interpretation is limited. The data were 192 
simply processed using MicroCal Origin software to obtain the protein melting temperature (Tm) and, 193 
from the area under the peak, enthalpy (ΔH). Isothermal titration calorimetry was conducted in a VP-194 
ITC titration micro-calorimeter (MicroCal, UK). All samples were equilibrated by dialysis against the 195 
same buffer (150 mM NaCl, pH 7.0) and de-gassed as above. The Alhydrogel suspension was placed 196 
in the stirred chamber (300 rpm) and rPA solution in the syringe. Titration was performed with 197 
injection volumes of 10 µl for 20 s and injection spacing of 200 s, a cell temperature of 25oC and 198 
(ΣFλ x λ)
ΣFλ
λm = 
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reference power of 15 μCal/sec. The ITC data were processed, including subtracting reference scans 199 
(rPA into buffer) from sample scans, in Origin software.  200 
 201 
Mouse Anthrax Challenge Assay 202 
The mouse anthrax challenge assay, which emulates the human immunological response to anthrax 203 
infection, was used for all release and stability testing of the rPA vaccine.  All investigations 204 
involving animals were carried out according to the requirements of the UK Home Office legislation 205 
and the Animal (Scientific Procedures) Act 1986. Potency was determined using a mouse challenge 206 
assay using a single immunization followed by subsequent challenge with anthrax STI spores. Female 207 
A/J mice (Harlan Laboratories, U.K.), between 7 and 12 weeks of age, were injected with either test 208 
rPA-AlOH vaccine (either 0.25mM phosphate or 4mM phosphate) or with a freshly formulated 209 
reference standard comprising rPA-AlOH.    During immunization, each dose was administered in a 210 
total volume of 0.1 ml, administered in two 0.05 ml aliquots intra-muscularly from the same syringe 211 
into each hind-limb. Both the reference and test items were administered as two parallel 4-point 212 
dilution series ranging between 0.2 and 0.004 ug/ml doses, with 15 mice/dose. The mice were 213 
transferred to the ACDP Level III isolator for spore challenge. At day 21 following the single 214 
immunization, each mouse was challenged with 2 x 106 Bacillus anthracis STI spores 215 
intraperitoneally (range of 0.9 to 5 x 106 spores) which is equivalent to a 2 x 103 median lethal dose. 216 
All immunizations and spore challenges were performed using a single operator. Following spore 217 
challenge, all animals were closely monitored for up to 8 days and the time to death was recorded. 218 
Humane end points were strictly observed for animals showing signs of disease.  219 
Potency was determined using a survival model, which describes the relationship between vaccine 220 
concentration and mouse survival and ED50 values were determined. In this study, the ED50 is the 221 
estimated concentration at which 50% of the mice survive to 8 days. For a single material the 222 
predictor is the log10 vaccine concentration and the response is the number of days survived by each 223 
mouse. For mice that survive until day 8 the survival time is censored, i.e. the model takes into 224 
account that they are alive on the final day of the test. With this model the survival time is assumed to 225 
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follow a lognormal distribution, which means that the log of survival time follows a normal 226 
distribution. 227 
For a single material the following parameters are defined for each concentration i ( 4,3,2,1=i ): 228 
• iC  the vaccine concentration for group i, 229 
• iN  the number of mice challenged for group i. iN  is usually 15. 230 
• ijS  the number of days the jth  mouse from group i survived, where iNj ,,2,1 = . ijS  231 
is censored at 8 days.  232 
The survival model for a given material can be expressed as: 233 
 ).(logβα))((log 10 CSe ×+=Ε  234 
The equation describes a straight line with slope β  and intercept α . 235 
Once α  and β  have been estimated it is possible to calculate the ED50 of the material. For the 236 
lognormal distribution this is equivalent to the concentration at which the mean log survival time is 237 
)8(log e  days. At the ED50 we have: 238 
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 242 
Long term Stability determination 243 
The stability of each of the materials was investigated using weighted linear regression. Each estimate 244 
of log ED50 was weighted by the inverse of the variance of the estimate, such that precise estimates 245 
were given more weight than imprecise estimates. The weighted linear regression produces a line of 246 
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best fit to the data, such that the intercept provides an estimate of the log ED50 at manufacture and the 247 
slope provides an estimate of the change in log ED50 per month. A p-value was calculated for the 248 
slope, indicating whether the log ED50 changes over time. All analysis was conducted using the 249 
statistical software R (version 2.12.1 for Windows). 250 
 251 
Results 252 
Phosphate Titration of Alhydrogel. 253 
The saturation curve of phosphate binding to Alhydrogel was determined in the absence of rPA. All 254 
added phosphate bound to the Alhydrogel until the saturation point was reached when residual free 255 
phosphate appeared in the supernatent. It was evident from the binding curve that, for 1.5 mg of 256 
Alhydrogel in 1ml, saturation was reached when 0.65 mol of phosphate had bound (around 1 mM 257 
[phosphate] in this experiment). This gives a saturation level of 0.43 mol of phosphate per mg of 258 
Alhydrogel (Figure 1). 259 
Langmuir Adsorption Isotherms 260 
The ligand exchange reaction introduces negative charge to the surface of Alhydrogel and to 261 
characterise the effect on rPA Alhydrogel interactions we determined the strength of binding 262 
(adsorption coefficient) and the binding capacity by fitting data to a Langmuir adsorption isotherm 263 
(10, 29). This analysis was performed on both non-modified and phosphate saturated Alhydrogel. 264 
When it was observed that rPA still bound to phosphate saturated Alhydrogel, we extended the 265 
analysis to examine the effect of free phosphate on the protein-adjuvant interaction. The 266 
concentrations of free phosphate tested were between 0 and 50 mM . In Langmuir analysis, the 267 
strength of binding is given by the adsorption coefficient, the higher the value of adsorption 268 
coefficient the stronger the interaction. For non-modified Alhydrogel, rPA had an adsorption 269 
coefficient of 215 ml/mg. This value substantially decreased in the presence of phosphate (Figure 270 
2A). Likewise, there was a sharp reduction in the binding capacity (Figure 2B). Both adsorption 271 
coefficient and binding capacity were further reduced by free phosphate, before reaching a steady 272 
state around 5 to 10mM phosphate.  273 
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To evaluate directly the effect of phosphate upon the normal vaccine formulation, rPA at 200 µg/ml 274 
was formulated with 2.6 mg/ml Alhydrogel at increasing concentrations of phosphate and the level of 275 
unbound rPA was determined using UV absorbance (Figure 2C). As expected, when the phosphate 276 
levels were increased, the levels of unbound rPA correspondingly increased. Whereas at 5 mM the 277 
unbound rPA content remained below 5%, this had increased to around 12% with 10 mM phosphate.  278 
Zeta potential measurements 279 
Changes in Alhydrogel surface charge (zeta potential) as a function of phosphate concentration, were 280 
measured using a Zetasizer Nano ZS (Malvern). The analysis was performed on Alhydrogel (2.6 281 
mg/ml) alone and with 200 µg/ml rPA bound to 2.6 mg/ml Alhydrogel with increasing concentrations 282 
of phosphate. As would be expected from previous studies (33), the zeta potential of Alhydrogel was 283 
positive at physiological pH. With increasing phosphate saturation, it rapidly declined and eventually 284 
become negative (Figure 3) with a point of zero charge at 2.5 mM phosphate. Alhydrogel with 285 
adsorbed rPA exhibited similar changes; however, the initial zeta potential of Alhydrogel with bound 286 
rPA had a lower value compared to that of Alhydrogel alone and the point of zero charge was 2.3 mM 287 
phosphate. This initial difference was attributed to the negative charge on the adsorbed protein. The 288 
zeta potential values for Alhydrogel and rPA-AlOH converged around 3.5 mM .  289 
 290 
Isothermal Titration Calorimetry of rPA Binding to Alhydrogel 291 
The modified adjuvant was prepared by treating Alhydrogel with phosphate to produce saturation 292 
levels of 10, 50 and 100 %, according to the phosphate saturation curve in Figure 1. Titration of non-293 
modified Alhydrogel with rPA gave a series of endothermic peaks (Figure 4A) whose magnitude 294 
decreased gradually through the titration due to a decrease of free binding sites on Alhydrogel. In 295 
stark contrast the binding of rPA to phosphate-saturated alhydrogel was exothermic and the adjuvant 296 
was more rapidly saturated with the protein, implying that fewer binding sites were available (Figure 297 
4B). Similarly, titration of 50% phosphate-saturated Alhydrogel was exothermic but the magnitude 298 
was less compared to that of phosphate-saturated Alhydrogel (Figure 4C). A complex result was 299 
observed with 10% phosphate-saturated Alhydrogel which presumably presents mixed binding 300 
surfaces to the rPA. The interaction was endothermic at the beginning of titration but gradually 301 
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changed to exothermic (Figure 4D), suggesting that the initial entropy driven interaction with AlOH 302 
was preferred over subsequent enthalpy driven binding to phosphate modified surfaces.  303 
 304 
Solid State Circular Dichroism 305 
Solid state (31, 34) far UV CD spectra of rPA-AlOH (Fig 5a) closely resembled that of soluble rPA 306 
(Chalton et al, 2007), indicating minimal secondary structure perturbation upon binding to 307 
Alhydrogel. Increasing phosphate concentrations did not significantly affect the spectrum. Near UV 308 
solid state CD spectra of rPA-AlOH at 0.25 mM phosphate, 4 mM phosphate and 10mM phosphate 309 
were also similar, with each showing the two prominent positive tryptophan CD bands at 284 nm and 310 
291 nm. These two bands, characteristic of rPA (31, 35), were weaker than in soluble rPA in solution 311 
(Figure 5B) and in the 10 mM phosphate sample two bands (272nm and 276nm) are observed that 312 
were not present with soluble rPA. In the phenylalanine region a broad positive band from 250-260 313 
nm was seen in soluble rPA, which sharpened when rPA was bound to Alhydrogel, irrespective of the 314 
phosphate concentration. Thus, the phosphate modification of the alhydrogel interaction has clear but 315 
subtle effects on the rPA tertiary structure. 316 
 317 
Differential Scanning Calorimetry (DSC) 318 
The transition temperature (Tm) and calorimetric enthalpy (ΔHcal) of rPA are strongly affected by 319 
binding to Alhydrogel (18, 23). Surprisingly, the protein had no measurable melting transition when it 320 
was adsorbed to non-modified or phosphate saturated Alhydrogel. However, as the free phosphate 321 
concentration increased there appeared a distinct thermal transition that eventually resembled the 322 
behaviour of free rPA (Figure 6A). Between 1 and 50 mM phosphate, the Tm rose from 43.3 0C to 323 
48.2 0C and ΔHcal increased from 31 kcal mol-1 to 139 kcal mol-1 (Figure 6B). The Tm and ΔHcal of 324 
non-adjuvanted rPA protein were 49.2 0C and 219 kcal mol-1 respectively. Plotting Tm and ΔHcal 325 
values against the fraction of bound protein revealed that these changes in thermodynamic parameters 326 
took place when > 90 % of rPA was still bound to Alhydrogel (Figure 6C). Conversely, above 10 mM 327 
phosphate, when protein binding was less than 90 % (Figure 2C), there were only minor changes in 328 
 14
Tm and ΔHcal. The phosphate concentration range when major thermodynamic changes occurred was 329 
1-10 mM, when the majority of the rPA was in the bound form. 330 
 331 
Tryptophan fluorescence  332 
The tryptophan emission spectrum of rPA on Alhydrogel was similar to that of free rPA, irrespective 333 
of phosphate concentration (supplementary data). All spectra exhibited their maximum near 330 nm 334 
and had the same barycentric mean values of 340.6 ± 0.1 nm (18). The tryptophan emission spectrum 335 
of rPA on Alhydrogel had weaker intensity compared to the emission spectrum of rPA without 336 
adjuvant, likely due to an inhomogeneous distribution of fluorophores in solution, the colloidal nature 337 
of the sample, and light scattering. Overall, these data demonstrate no measurable change in the 338 
protein tertiary structure due to phosphate (Supplementary data).  339 
Protein unfolding was monitored by tryptophan fluorescence while increasing the temperature from 340 
25 0C to 65 0C at the rate of 1 0C min-1 (18). In samples containing non-modified, 50 % and 100 % 341 
phosphate-saturated Alhydrogel, the protein had no distinct unfolding transition and exhibited only 342 
small changes in fluorescence most of which were due to the quenching effect of higher temperatures 343 
(Figure 7 A). However, with free phosphate, i.e. around 2.6 mM, rPA had a well-defined transition 344 
region between 40 0C and 50 0C (Figure 7 B). Note that increasing phosphate concentration shifted the 345 
transition midpoint from 43.5 0C to 48.0 0C, compared to the 48.5 0C transition temperature of non-346 
adjuvanted rPA. Also, it should be noted that in 10 mM phosphate nearly 90 % of rPA was bound to 347 
Alhydrogel.  348 
 349 
Measurements of Potency and Stability 350 
For practical and ethical reasons, the study the effect of phosphate ions on the potency of the rPA-351 
AlOH formulation used only two formulations, namely 0.25 mM and 4 mM phosphate rPA-AlOH. 352 
The 0.25 mM phosphate rPA-AlOH represented an unsaturated formulation where the Alhydrogel 353 
retained surface hydroxyl groups, whereas, in contrast, the 4 mM phosphate rPA-AlOH represented a 354 
phosphate-saturated Alhydrogel plus free/excess phosphate. The average pH values of the bulk 355 
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solutions were 6.0 ±0.3 (n=4) and 7.1 ± 0.1 (n=7) for the 0.25 mM and 4 mM phosphate rPA-AlOH, 356 
respectively.  357 
Potency was determined using the anthrax mouse-challenge assay, evaluating several batches of these 358 
two formulation prototypes immediately following manufacture. With each potency analysis a four-359 
fold dilution curve was performed. The ED50 values were estimated by fitting a survival analysis 360 
model to the results of the potency assay, using a model that assumes the survival times have a log 361 
normal distribution and that there is a linear relationship between log dose and log survival time 362 
(Table 1) (36). Note that for three of the 4 mM phosphate rPA-AlOH, batches more than one 363 
measurement of ED50 was taken at release and this data has been incorporated into the statistical 364 
analysis. The weighted mean ED50 for the 0.25 mM phosphate rPA-AlOH batches was 0.21 365 
μg/0.1mL (back-transformed from the log10 ED50 mean value of -0.679), whereas for the 4 mM 366 
phosphate rPA-AlOH the value was 0.04 μg/0.1mL (log10 ED50 mean value of -1.398). The weighted 367 
mean was used (weighted by the inverse of the variance of the log10 ED50) to down weight less 368 
precise log10 ED50 estimates. Statistical analysis using ANOVA indicated that at release 4 mM 369 
phosphate rPA-AlOH was significantly more potent than 0.25mM phosphate rPA-AlOH, as shown by 370 
a difference in log ED50 (p=0.006). The ANOVA took batch and operator into account. Comparison 371 
of the mean ED50 values indicated that the 4 mM phosphate rPA-AlOH was 5.25 fold more potent 372 
than the 0.25mM phosphate formulation. 373 
In addition long term, real time stability studies were performed on a batch of 0.25 mM phosphate 374 
rPA-AlOH and one of 4 mM phosphate rPA-AlOH. In accordance with ICH Harmonised Tripartite 375 
Guidelines Q1A(R2) (Stability Testing of New Drug Substances and Products) (37), the materials 376 
were stored for at least three years at 2-8oC under controlled conditions, which were monitored to 377 
ensure temperature compliance. During the 3 years storage, samples were analysed for potency using 378 
the mouse anthrax challenge assay. Trending analysis was performed after three years to determine 379 
the overall stability of the two vaccine formulations and the data are presented in Figure 8.  380 
Linear regression analysis of the 0.25mM phosphate rPA-AlOH after 39 months storage at 2-8oC 381 
revealed no evidence of an increase in log ED50 post manufacture (intercept = -0.414 (ED50 of 382 
0.385); slope = 0.007; p = 0.480). Likewise, the 4mM phosphate rPA-AlOH exhibited no evidence of 383 
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a significant increase in logED50 after 36 months storage at 2-8oC (intercept = -1.277 (ED50 of 384 
0.0528); slope = 0.007; p = 0.673). Trending analysis was also performed on three batches of the 4 385 
mM phosphate rPA-AlOH formulation to provide further supporting data for stability. Using relative 386 
potency (RP) against a freshly formulated rPA-AlOH standard, the rPA-AlOH was shown to be stable 387 
for at least 37 months (Supplementary Data). 388 
  389 
Discussion 390 
Aluminium based adjuvants are extensively used in the formulation of a range of vaccine types, 391 
including sub-unit vaccines, being both effective in boosting immune responses and safe for use in 392 
man (14). Although mainly used against infectious diseases they are also effective in anti-cancer 393 
vaccines (38). Aluminium oxyhydroxide formulations, such as Alhydrogel, are the most commonly 394 
used since they are positively charged at physiological pH and bind most antigens, which tend to be 395 
acidic. A significant feature of aluminium oxyhydroxide chemistry is the ligand exchange reaction, 396 
whereby surface hydroxyl groups are readily exchanged for phosphate ions (26). Consequently, the 397 
surface layer of the aluminium oxyhydroxide is converted to aluminium phosphate, radically changing 398 
the surface charge properties of the Alhydrogel particles. Consequently, we performed a series of 399 
studies to explore how phosphate modification of Alhydrogel (27) affects the properties of the 400 
vaccine. Upon mixing, phosphate ions rapidly bound to Alhydrogel particles until a saturation point 401 
was reached, with 0.43 µmol phosphate saturating 12.8 µmol (1 mg) of Alhydrogel. Since there are 2 402 
moles of hydroxyl groups per 1 mole of Alhydrogel, the theoretical maximum phosphate saturation 403 
requires 12.8 x 2, i.e. 25.6 µmol phosphate. Thus, we assume that only 1.7% of potential reactive 404 
groups were on the surface and available for phosphate binding. This confirms that the majority of the 405 
hydroxyl groups are not surface exposed, but contained within the colloidal particle itself (21).  406 
However, despite the reversal in surface charge (Figure 3), it was surprising that even with supra-407 
saturating concentrations of phosphate the acidic rPA protein, at the formulation density of 200 µg per 408 
2.6 mg of AlOH, was still predominantly bound (>90%) to the Alhydrogel particles (Figure 3). One 409 
possible explanation might be due to the variety of charged groups on rPA. Although acidic, with a pI 410 
of 5.6, rPA still contains 85 cationic (Arg + Lys) versus 96 anionic (Asp + Glu) side chains and the 411 
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former may be sufficient to bind to the negatively charged phosphate groups in a more selective 412 
manner. The effects of increasing phosphate concentration extended beyond the point of surface 413 
saturation and suggest that the surface charge of the Alhydrogel is not purely determined by the extent 414 
of ligand exchange. There is thus also a role for free phosphate in modulating the interaction between 415 
the rPA and the Alhydrogel surface.  416 
On native Alhydrogel the interaction of rPA with the hydroxyl groups was endothermic meaning that 417 
it is driven by an increase in entropy, an effect often attributed to dehydration effects. This would 418 
imply that there is a significant reduction of water accessible surface upon rPA binding (39, 40). In 419 
contrast, above the point of phosphate saturation, the reaction became exothermic and was no longer 420 
driven solely by entropy. This enthalpy favoured interaction could be associated with the formation of 421 
direct non-covalent bonds at the particle surface. At sub-saturating phosphate concentrations, the 422 
thermodynamics are complex and at 10% saturation there is evidence for a genuinely mixed surface 423 
offering high (endothermic) and low (exothermic) affinity sites. 424 
On phosphate-saturated Alhydrogel cooperative thermal unfolding (18, 23), was more evident and 425 
became increasingly pronounced with increased free phosphate although the protein was still bound to 426 
the Alhydrogel. Increasing phosphate concentration thus appears to surface bound proteins to behave 427 
as though in solution. Thus enhanced hydration (41) could explain both the ITC data and the increased 428 
protein thermostability. 429 
Of paramount importance is role of phosphate in the potency of the rPA sub-unit vaccine and its 430 
stability when stored under refrigeration. The phosphate sub-saturated 0.25 mM phosphate rPA-AlOH 431 
was significantly less potent than that of 4 mM phosphate rPA-AlOH and one contrasting feature of 432 
the two formulations was the pH of the bulk solution, the 0.25 mM phosphate rPA-AlOH having a pH 433 
of 5.9 and the 4 mM phosphate rPA-AlOH around 7.1. Consequently, the differing bulk solution pH 434 
might explain the differences in ED50 values, particularly since rPA is acid-labile (35, 42). However, 435 
the biophysical analysis of the protein structure of rPA-AlOH in low phosphate conditions does not 436 
support any major acid-induced transformation of the protein structure (31, 35). Furthermore, with 437 
0.25 mM phosphate rPA-AlOH, the Alhydrogel surface and bound antigen would have a local pH 438 
approximately 2 units higher due to the positive surface charge attracting hydroxyl anions (27). In 439 
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contrast, the negatively charged phosphate saturated Alhydrogel would be expected to attract protons, 440 
and hence have a more acidic microenvironment compared to the bulk solution.  441 
Hem and co-workers have hypothesized that the immunogenic response to an aluminium adjuvantized 442 
protein antigen is inversely related to the adsorption coefficient (10). They and others have also 443 
shown that antigens can be rapidly released from the Alhydrogel depot implying that the directly 444 
interacting adjuvant and antigen do not stimulate the immune response(11, 13, 43). Consequently, the 445 
ability of phosphate to modulate the adsorption coefficient of an acidic protein antigen and aluminium 446 
oxyhydroxide adjuvants might appear to be irrelevant. However, enhanced immunogenicity was seen 447 
when a recombinant Candida antigen (rAls3p-N) was diluted with phosphate buffered saline as 448 
opposed to saline alone (44). Similarly, phosphate modulation of aluminium oxyhydroxide in both 449 
hepatitis B surface antigen and HIV 1 SF162dV2gp140 subunit vaccines demonstrated an 450 
enhancement of immunogenicity (8, 9).  451 
There have been several proposed mechanisms of action for aluminium-containing adjuvants, 452 
including: a depot in tissues to produce prolonged exposure (45), an enhanced delivery of antigen to 453 
antigen presenting cells (46), an induction of uric acid for activating inflammatory dendritic cells (47), 454 
and an enhanced proteolytic processing by the immune system due to destabilisation of the antigen 455 
structure (23). However, compelling evidence has recently been produced to demonstrate that 456 
aluminium-containing adjuvants have direct effects on dendritic cells (6, 7, 48). Certainly a weakly 457 
bound antigen, as found in phosphate saturated Alhydrogel, would be more likely to be internalized 458 
and processed by the dendritic cells. It should be noted that the physiological level of phosphate is 459 
strictly regulated at 0.8 to 1.4 mM (49). Upon injection, into this phosphate concentration, exposed 460 
surface hydroxyl groups are likely to be replaced and if not phosphate saturated beforehand, the 461 
aluminium oxyhydroxide will saturate following injection. Surprisingly , our data show that the 462 
difference between the 0.25 mM phosphate rPA-AlOH and 4 mM phosphate rPA-AlOH formulations 463 
persists. It is possible that binding of the rPA to the Alhydrogel in sub-saturating conditions occludes 464 
hydroxyl groups and prevents subsequent phosphate exchange. Under such circumstances the stronger 465 
binding conditions may prevail even when later exposed to physiological phosphate concentrations 466 
Although Iyer et al showed that aluminium adjuvant interactions with a basic protein (lysozyme) 467 
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could be reversed in interstitial fluid, with acidic ovalbumin this was only true of freshly formulated 468 
mixtures and older samples did not release antigen (50). Thus if both rPA (pI= 5.6) and ovalbumin (pI 469 
= 4.7) rearrange slowly on the adjuvant surface, the effect of phosphate we observe may be the 470 
indefinite maintenance of the loose interaction state. 471 
 472 
Overall, the results are consistent with previous data showing that phosphate is a beneficial 473 
modulating agent for rPA binding to Alhydrogel. This study however goes much further in clarifying 474 
the role of phosphate which could be explained by weaker interactions allowing a more complete 475 
water layer to be formed between the protein and adjuvant. Thus the hypothesis of Hem and co-476 
workers that the immunogenic response to an aluminium adjuvantized protein antigen is inversely 477 
related to the adsorption coefficient (Hansen et al, 2007) is strongly confirmed but also extended to 478 
include the physical effects on the protein and the effect on potency over a long period. Combined 479 
with recent data that some adjuvant protein interactions rapidly dissociate upon injection (13) it 480 
appears that the strongest aluminium adjuvant effects are likely to be via weakly attached or easily 481 
released, native state antigen proteins. 482 
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Figure legends 642 
 643 
Figure 1: Saturation curve for binding of phosphate to Alhydrogel. These data were fitted to the 644 
Boltzmann Sigmoid equation using non-linear regression analysis in the Origin software (version 7.5, 645 
OriginLab Corporation). The insert shows raw absorbance data obtained in the spectrophotometric 646 
phosphate assay.   647 
Figure 2: Results from linear regression fits to the Langmuir adsorption isotherm showing the effect 648 
of phosphate on (A) adsorption coefficient; (B) binding capacity of Alhydrogel for rPA and (C) 649 
Fraction of rPA binding to Alhydrogel in samples of 200ug/ml rPA and 2.6mg/ml Alhydrogel. 650 
 Figure 3: Zeta potential: curves exhibit the effect of phosphate on zeta potential of Alhydrogel with 651 
and without rPA. 652 
Figure 4: Titration of Alhydrogel with rPA showing thermograms for : A) Non-modified Alhydrogel; 653 
B) 100 % phosphate saturated Alhydrogel; C) 50 % phosphate saturated Alhydrogel; and D) 10 % 654 
phosphate saturated Alhydrogel. Inset diagrams show the likely surface chemistry of the variously 655 
saturated adjuvants. 656 
Figure 5: The effect of phosphate on Solid state Circular Dichroism of 200ug/ml rPA with 2.6mg/ml 657 
Alhydrogel: (A) far UV CD spectra and (B) near UV CD 658 
Figure 6: Phosphate effect on the structure and stability of adjuvanted rPA: A) An overlay showing 659 
DSC endotherms of rPA on Alhydrogel in 0, 2, 5, 10, 20, 45 mM phosphate and rPA without adjuvant 660 
respectively; B) Tm and ΔHcal values as function of phosphate concentration; C) Tm and ΔHcal change 661 
as fraction of bound rPA. Samples contained 0.3 mg/ml rPA and 3 mg/ml phosphate saturated 662 
Alhydrogel.  663 
Figure 7: Tryptophan fluorescence: thermal denaturation of rPA on Alhydrogel: A) rPA adsorbed to 664 
non-modified, 50 % and 100 % phosphate-saturated Alhydrogel; B) rPA on Alhydrogel in 1-10 mM 665 
free phosphate. The thermal transition of non-adjuvanted rPA (solid line) occurred at 48.5 0C. All 666 
curves are normalised to values of 1 at 25oC and 0 at 65oC. 667 
 668 
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Figure 8: logED50 Stability data for (A) 0.25mM Phosphate rPA-AlOH and (B) 4mM Phosphate 669 
rPA-AlOH, both stored at 2-8oC. The error bars represent ± SD; the solid line is the trending line and 670 
the broken line is the one-sided 95% confidence interval. 671 
 672 
 
Table 1: Summary of potency data at release for 0.25 mM phosphate and 4 mM phosphate rPA-
AlOH in Final Drug Product (FDP). 
Material Type Batch n LogED50 SDLogED50 ED50µg/0.1mL 
0.25mM PO4 FDP 
Batch 1 1 -0.130 0.285 
  
Batch 2 1 -1.681 0.514 
Batch 3 1 -0.484 0.193 
Batch 4 1 -1.338 0.288 
Weighted Mean ED50 0.25mM phosphate FDP batches 0.21 
4mM PO4 FDP  
Batch 5 1 -2.202 0.789 
  
Batch 6 4 
-1.133 0.154 
-1.367 0.229 
-1.862 0.248 
-1.273 0.159 
Batch 7 4 
-1.420 0.129 
-1.640 1.117 
-1.605 0.220 
-1.451 0.203 
Batch 8 1 0.348 0.594 
Batch 9 2 
-0.505 0.241 
-1.419 0.242 
Batch 10 1 -1.175 0.235 
Batch 11 1 -1.397 0.265 
Weighted Mean ED50 4mM phosphate FDP batches 0.04 
 








